COVID-19Base: A knowledgebase to explore biomedical entities related to
  COVID-19 by Khan, Junaed Younus et al.
 1 
 
COVID-19Base: A knowledgebase to 
explore biomedical entities related to 
COVID-19 
 
 
Junaed Younus Khan1, Md. Tawkat Islam Khondaker1, Iram Tazim Hoque1, Hamada Al-
Absi2, Mohammad Saifur Rahman1, Tanvir Alam2,*, M. Sohel Rahman1 
 
1Department of Computer Science and Engineering, Bangladesh University of 
Engineering and Technology, Dhaka, Bangladesh. 
2Information and Computing Technology Division, College of Science and Engineering, 
Hamad Bin Khalifa University, Doha, Qatar. 
 
*To whom correspondence should be addressed. 
 
Abstract 
We are presenting COVID-19Base, a knowledgebase highlighting the biomedical entities related to 
COVID-19 disease based on literature mining. To develop COVID-19Base, we mine the information 
from publicly available scientific literature and related public resources. We considered seven topic-
specific dictionaries, including human genes, human miRNAs, human lncRNAs, diseases, Protein 
Databank, drugs, and drug side effects, are integrated to mine all scientific evidence related to 
COVID-19. We have employed an automated literature mining and labeling system through a novel 
approach to measure the effectiveness of drugs against diseases based on natural language 
processing, sentiment analysis, and deep learning. To the best of our knowledge, this is the first 
knowledgebase dedicated to COVID-19, which integrates such large variety of related biomedical 
entities through literature mining.  Proper investigation of the mined biomedical entities along with 
the identified interactions among those, reported in COVID-19Base, would help the research 
community to discover possible ways for the therapeutic treatment of COVID-19.  
Availability: COVID-19Base is available at: http://77.68.43.135:96/. 
Contact: talam@hbku.edu.qa   
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Introduction 
 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) initially spread widely in China, 
then in Italy, and, now in other parts of the world, causing coronavirus disease 2019 (COVID-19) [1]. 
SARS-CoV-2 is the novel coronavirus that causes the alarming pandemic of COVID-19 since 
February 2020 [2]. While the novel coronaviruses (SARS-CoV-2) have gained enormous attention 
and grave concern as a consequence of the current worldwide COVID-19 pandemic situation, other 
known human coronaviruses, beta coronaviruses (SARS-CoV, MERS, OC43, HKU1) and alpha 
coronaviruses (229E, NL63),  historically, caused a significant level of public-health concerns and 
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resulted in severe respiratory syndrome for the patients as well  [3, 4]. To combat the global lethality 
of COVID-19, it demands an urgent solution for the detection and therapeutic treatment, which 
requires a comprehensive experimental elucidation of biomedical entities (e.g., genes, non-coding 
RNAs (ncRNA), viruses, drugs, etc.) [5] that are involved in this disease. But this is a relatively slow 
process due to the inherent nature of the experimental validation. As an alternative, in silico 
methods are also proposed by multiple research groups [6, 7]. Still, it is also a daunting task due to a 
large number of possible combinations of biomedical entities that need to be examined [8]. To 
mediate these two extreme experimental setups, and at the same time, to enable a comprehensive 
exploration of potential therapeutic treatments, knowledgebase based solutions are proposed, as 
part of this study, for the scientific community to focus on a smaller number of biomedical entities 
that may guide to the discovery of a novel solution of the COVID-19 treatment.  
 
There exist databases that focused on the virus-related diseases for multiple hosts. For example, in 
ViRBase [9], the authors highlighted the association between non-coding RNAs (ncRNAs) and 
viruses in 20 hosts. VISDB database, based on literature mining, integrated the virus interaction site 
in humans for five DNA oncoviruses and four RNA retroviruses [10]. The Virus Pathogen Resources 
(VIPR), developed a portal collecting a comprehensive set of information related to coronavirus and 
hepatitis C virus (HCV), other viruses [11, 12] . But none of the mentioned databases are much 
useful for COVID-19/SARS-CoV-2, as those databases were not specific to novel coronavirus, or they 
provide very limited information about the associated genes, ncRNA or do not cover other 
associated factors that are involved in coronavirus-related diseases, drugs and their side effects. 
Moreover, there exists no such knowledgebase that has integrated all biomedical entities specific to 
COVID-19/SARS-CoV-2. To fill this gap, we develop the first comprehensive knowledgebase, 
COVID-19Base, that integrates several biomedical entities that are associated with COVID-
19/SARS-CoV-2 from the scientific literature.  
 
In COVID-19Base, we use a dictionary-based approach to find the association of seven different 
thematic areas related to COVID-19/SARS-CoV-2 and other coronavirus-related diseases in 
humans. In COVID-19Base, we not only highlight the biomedical terms that are mentioned in the 
literature, but we also identify “term pairs” based on their co-occurrence, which will allow the 
scientific community to investigate in depth the association between term pairs like disease-gene, 
disease-drug, disease-ncRNA, etc. While careful manual curation of the identified associations is the 
ultimate goal, in COVID-19Base, we propose and implement a novel approach to estimate the 
effectiveness of drug for diseases based on natural language processing, sentiment analysis, and 
deep learning. We also apply the concept of cosine similarity [36] to confidently infer the 
associations between diseases and genes, lncRNAs, miRNAs. The knowledgebase, we developed, will 
support the researcher around the world to discover the existing knowledge and find a solution for 
this pandemic. 
 
Materials and Methods 
For this study, we considered COVID-19 Open Research Dataset (CORD-19), generated by Allen 
Institute of AI (publicly available at https://pages.semanticscholar.org/coronavirus-research) . The 
dataset contains over 44K scholarly articles, related to COVID-19 and the coronavirus family of 
viruses. The dataset was collected using query: "COVID-19" OR Coronavirus OR "Corona virus" OR 
"2019-nCoV" OR "SARS-CoV" OR "MERS-CoV" OR “Severe Acute Respiratory Syndrome” OR 
“Middle East Respiratory Syndrome” against PubMed, PubMed Central (PMC), bioRxiv and 
medRxiv pre-prints and it covers major part of all research articles related to COVID-19 and other 
coronavirus (e.g. MERS, SARS, etc.) till 27-03-2020. We considered the abstract and full body from 
the research articles for downstream analysis.  
Source of dictionaries: Genes (HGNC), miRNA (miRBase), lncRNA(LNCipedia), PDB, disease 
(DO) , drug (DrugBank), side effect (SIDER) 
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Extracting Disease-Drug Interactions 
We extract disease-drug interactions from the CORD-19 literature and classify them in two 
categories (labels): Positive and Negative. The positive label means the drug is somewhat effective 
for curing the disease, and the negative label means the opposite. We also determine a confidence 
score which indicates our level of confidence for that automatic label. Fig. 1 shows the workflow of 
extracting disease-drug interactions and predicting the effectiveness of drugs against diseases with 
confidence scores. 
Disease and Drug Names Extraction 
To extract relevant disease-drug pairs from the CORD-19 literature, we employ a dictionary-based 
approach to detect mentions of diseases and drugs in the literature. We use Disease Ontology [13] 
and DrugBank [14] to prepare the disease and drug dictionaries. We leverage the Aho-Corasick 
algorithm [15] to search the drug and disease names considering the large size of drug and disease 
dictionaries and the corpus itself. The Aho-Corasick algorithm is a string searching algorithm that 
efficiently locates multiple patterns in a large blob of text. The time complexity of the algorithm is 
O(n + m + z), where n is the length of the text, m is the total length of all the patterns to be searched, 
and z is the total number of occurrences of the patterns in the text. 
 
Figure 1.  Flowchart of extracting disease-drug interactions and predicting the effectiveness of 
drugs against diseases with confidence scores.  
Disease-Drug Pairs Extraction 
After extracting the disease and drug names separately, we want to mine the literature and identify 
the sentences that contain the disease and drug pairs to semantically evaluate their interactions. For 
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this purpose, we search for every disease-drug pair from our disease and drug list in the CORD-19 
literature and collect every sentence where a co-occurrence is found. Then we create a document for 
every disease-drug pair combining all extracted sentences. Thus we build a disease-drug pair to 
document mapping. We do not use any pattern-based approach here as done in the paper [16] as 
this could result in missing a good number of sentences containing disease-drug pairs.  
Anomaly Removal  
As we automatically extract the sentences containing the disease-drug pairs, there is a possibility of 
aberration in our extracted data. So we decide to check and remove any abnormality from our 
collected data before going into the next stage of the pipeline. We use unsupervised anomaly 
detection [17] for doing this job. Unsupervised anomaly detection technique detects anomalies in an 
unlabeled dataset by looking for instances that seem to fit the least to the remainder of the dataset 
under the assumption that the majority of the instances in the dataset are ‘normal’. We use K-Means 
clustering algorithm [18] as it has been used for anomaly detection in several studies [19, 20, 21, 22, 
23]. We proceed as follows. First, we use Doc2Vec [24] to create a numeric representation of each 
document associated with each disease-drug pair. Then we fit these representations into our K-
means model and observe two clear clusters of easily discriminable sizes, where the smaller one 
consists of only 161 instances. As we know that anomalies differ from the normal instances 
significantly and occur very rarely in the data, we can assume that the instances of the smaller 
cluster are indeed anomalies. We also check a number of instances manually to verify our 
assumption. We discard these 161 instances from any further consideration. 
Sentiment Analysis 
We apply sentiment analysis to automatically assess the effectiveness of a drug to treat a particular 
disease in the context of each extracted drug-disease pair. First, we apply the concept of transfer 
learning. We use TextBlob [25] which is a pre-trained sentiment analysis tool provided as a Python 
library. However, it shows some inconsistency in some cases as expected from a pre-trained model 
and we feel the necessity of unsupervised sentiment analysis which is the second model of our 
pipeline. We get a polarity score from the TextBlob model and a sentiment rate from our 
unsupervised model for each disease-drug pair which are subsequently fed to our Neural Network 
model to predict the final label. 
TextBlob model: TextBlob is a Python library that is widely used in natural language processing 
tasks such as POS tagging, noun phrase extraction, sentiment analysis, classification, translation, 
and more. Given the sentences that we mined for each disease-drug pair as input, TextBlob gives a 
polarity score in the range between -1 and 1. We record the polarity scores for each disease-drug to 
use it as a feature for our Neural Network model. 
Unsupervised model: We use the concept of K-means clustering again for unsupervised 
sentiment analysis. First, we train the Word2Vec [26] model with our mined literature and get a 
vector representation of every word. Then we run K-means clustering on the estimated word vectors 
and find two clusters (positive and negative). The positive cluster is decided on the basis of the 
presence of several positive words (in the context of a disease-rug pair) in it such as ‘cure’, 
‘preclude’, ‘inhibit’, ‘prescribe’, ‘reduce’, ‘modest’, etc. On the other hand, the negative cluster 
contains words like ‘risky’, ‘kill’, ‘danger’, etc. Then we assign each word a sentiment value, either +1 
or -1, based on the cluster (positive or negative) they belong to. We weigh this value by dividing it by 
the distance between the word and the centroid of its cluster to describe the extent of its potential 
positive or negative-ness. Then we calculate the tf-idf score [27, 28] of each word in the sentence 
collection to consider the significance of the unique words. Next, we build a tf-idf representation, T, 
for each disease-drug pair by replacing each word of the corresponding sentences with its tf-idf 
score and a sentiment value representation, S, by replacing each word with its sentiment value. 
Finally, we take their dot product (T○S) as the final sentiment rate of our unsupervised model. 
 5 
 
Neural Network Model for Automatic Label and Confidence Score 
We use a Deep Neural Network (DNN) model to automatically predict the label and confidence 
score for our disease-drug pairs.  Earlier studies [29, 30] also used DNN models on small labeled 
data and achieved promising results.  
Training data: We manually labeled 200 disease-drug pairs to train our Neural Network model. 
Among them, there were 110 positive instances and the rest were negative. 
Input features: We use the polarity or sentiment score given by the TextBlob and unsupervised 
models as the input features for our Neural Network model along with the minimum distance 
between the disease and drug term in the corresponding document. 
Model setup and output: The DNN structure used in this study is similar to that shown in Fig. 2. 
It consists of 1 input layer with 3 neurons (each neuron corresponds to one input feature), 2 hidden 
layers with 8 and 4 neurons respectively, and 1 output layer containing 1 neuron for binary 
classification (positive or negative). The transfer functions of the first and second hidden layers are 
Rectified Linear Unit (ReLU) [31] and Hyperbolic Tangent function (tanh) [32] respectively. The 
transfer function of the output layer is a Sigmoid function [33]. We train the DNN model using 
Xavier initialization [34] which tries to make the variance of the outputs of a layer to be equal to the 
variance of its inputs. We use Adam optimizer [35] and the maximum training epoch is set to 500. 
We split our labeled data into training and test sets on an 80:20 ratio. We train our model on the 
training data and achieve 75% accuracy on the test set.  
 
Figure 2. Schematic diagram of the deep neural network used to predict the effectiveness of drugs 
against diseases. 
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Extracting Disease-Gene Associations 
Fig. 3 shows the workflow of extracting disease-gene associations. We extract gene names along with 
lncRNAs and miRNAs from the CORD-19 literature in a dictionary-based approach using HGNC 
[40], LNCipedia [41], and miRBase [42]. Then we extract their associations with diseases in a 
similar process that we have used to extract the disease-drug pairs and collected all the abstracts 
where a co-occurrence was found. Next, we apply the concept of cosine similarity [36] to confidently 
infer the associations. We transformed each disease into vector V1, each gene (and lncRNA, miRNA) 
into vector V2, and then calculated the cosine similarity of V1 and V2 for each pair. To create the 
vector representations, we train a Word2Vec model with all the collected abstracts.  We use the 
DisGeNET [37] database as the gold standard to evaluate the performance of cosine similarity in 
predicting the gene-disease linkage. First, we calculate the maximum, average, and minimum cosine 
similarity of the pairs that are common both in our findings and in the DisGeNET database. We find 
that 99.7% of the newly discovered pairs lie within this range (in terms of cosine similarity). We 
further classify the associations in three classes (high, medium, and low) in terms of confidence as 
follows: pairs having cosine similarity closest to the maximum (minimum) of the known ones are 
considered as high (low) confidence associations,  and the remaining ones (closest to the average) as 
medium confidence associations. Moreover, pairs that are also found in the DisGeNET database are 
labeled as verified associations.  
 
Figure 3.  Flowchart of extracting disease-gene, disease-lncRNA, disease-miRNA associations and 
determining their confidence levels. 
Extracting Drug-Protein Associations 
We also extract drug-protein associations from the CORD-19 literature applying the same co-
occurrence based approach as mentioned above. We use PDB Ids from the Protein Data Bank [38] 
for extracting protein names. Unlike the disease-gene associations, we do not apply the concept of 
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cosine similarity here as we do not find any suitable dataset that can be used as the gold standard in 
this case.  
Extracting Side-effects of Drugs 
 
The drugs we are suggesting through this literature mining may come with different side-effects. 
Therefore, we also explore the possible side-effects of the drugs. We collect the drugs with the 
corresponding side-effects from SIDER [39] and map the drug names with the drugs mentioned in 
the CORD-19 literature to extract the possible side-effects. 
 
Results 
 
Association between pair of terms in COVID-19Base 
 
We have mined 1811 drugs, 1219 diseases, 1703 genes, 11 lncRNAs, 9 miRNAs, and 70 PDBs from the 
CORD-19 literature. Table 1 summarizes the interactions or associations between different entities. 
Among the disease-drug pairs, 11480 are found to be positive and 1273, negative. Among the 
disease-gene associations, 1977 are verified (V), 40 associations are found with high-confidence (H), 
15509 with medium-confidence (M), and 7771 with low-confidence (L). More results are available 
in Table 1. Majority share of the data is labeled automatically following the methodology reported in 
the Methods section and complete manual curation is planned in subsequent versions. Notably, a tiny 
part (1.5%) of the findings have already been manually curated. 
 
Table 1. Pairs of terms as identified in the analyzed set of documents. Here V, H, M 
and L means Verified, High-, Medium- and Low-confidence associations respectively. 
+ve (-ve) indicates an (not) effective association. 
Interaction/Association # of extracted 
pairs of terms 
Disease-Drug              12753 (11480+ve, 1273-ve) 
Disease-Gene 25297 (1977 V, 40 H, 15509 M, 7771 L ) 
Disease-lncRNA              49 ( 2 V, 1 H, 30 M, 16 L ) 
Disease-miRNA              57 ( 29 M, 28  L ) 
Drug-PDB              288 
           
In the rest of this section, we discuss two of the interesting and useful findings using COVID-
19Base in the context of drug exploration for COVID-19. 
 
Remdesivir as the top ranked drug for COVID-19 in COVID-19Base 
 
As a case study, we find Remdesivir as a positive (i.e., effective) drug for COVID-19, automatically 
labeled as such through our pipeline with a confidence score of 75.86%. Thus COVID-19Base 
suggests Remdesivir as a promising drug for further investigation for treating COVID-19. 
Interestingly, it is recently being considered as the most effective drug for treating COVID-19. 
Notably, Remdesivir is an antiviral drug originally developed for Ebola treatment. It prevents viral 
replication by blocking an enzyme called polymerase and thus limits the spread of the disease. A 
recent clinical trial conducted by the National Institute of Allergy and Infectious Diseases (NIAID) 
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shows that Remdesivir helps COVID-19 patients recover faster and improves their survival rates. 
Adult patients, treated with Remdesivir, were found to recover four days faster, an improvement of 
31% compared to other patients and the overall death rate dropped from 11.6% to 8%.1 
Hydroxychloroquine as a possible treatment for COVID-19 
Anti-malaria drug Hydroxychloroquine, which is one of the most talked-about drugs for treating 
COVID-19, has also been found in our mining. Our model finds it as a positive (i.e., effective) drug 
with 57.89% confidence (note the significantly lower confidence score than that of Remdesivir). But 
it is also revealed from COVID-19Base that this drug has 111 side-effects including  Anaemia, 
Haemorrhage,  Liver disorder, Hepatitis fulminant, Cardiomyopathy, Cardiac failure, etc., which 
makes it a risky option especially for patients with heart and liver complications. Informatively, 
although the US Food and Drugs Administration (FDA) had previously granted authorization to use 
this drug for Covid-19, it recently cautions against its use outside of the hospital setting or a clinical 
trial due to its’ side effects and risk factors.2  
Availability 
COVID-19Base is available at: http://77.68.43.135:96/ .  As the number of scientific publications, 
particularly, on COVID-19 is surging, we will update the knowledgebase on a monthly basis and 
integrate all the recent updates in the knowledgebase. Additionally, a manually curation drive is 
underway and to facilitate that a limited sentence-wise feedback mechanism (from the esteemed 
users) is also incorporated in the software. 
Limitations 
 
While complete manual curation is the ideal goal, due to time and cost constraints we have employed 
a novel sophisticated automated approach to prepare COVID-19Base and make it available for the 
scientific community. However, this comes naturally with some errors due to inherent limitations of 
the methods and approaches adopted. This is why the identified inferences/associations are made 
available to the users for review to facilitate a feedback mechanism (from the esteemed users) in the 
COVID-19Base. 
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